On November 3, Rytis V. Urbonas, co-founder of Sanobiotec, participated in a trade mission in Basel, Switzerland on Life sciences partnership opportunities: Innovative ecosystem co-creation with Lithuanian leaders.
Ranked among the top five most innovative countries, the Swiss market attracts Lithuanian biotechnologies companies. Meanwhile, the Lithuanian life sciences sector, one of the most promising and priority sectors of the Lithuanian economy, is receiving worldwide attention for industry talents, a favorable business environment, innovative research, and technologies.
The purpose of participating in the trade mission in Switzerland was to explore the partnership opportunities among the leading Swiss life sciences companies and Sanobiotec – one of the world’s leading biotechnology companies in rare cannabinoid research and manufacturing.
“Sanobiotec currently grows at an accelerated rate, plans pre-clinical trials with minor cannabinoids, and exports our products to 15 countries around the world, including Switzerland. Thus, we already have ties with the businesses in the country. However, we believe that co-creation is essential in our field and we are open to new partnership opportunities in the (pre-)clinical trials field”, comments Rytis V. Urbonas.
Rare cannabinoids are used in various industries as an ingredient – in pharmaceuticals, food supplements, cosmetics, pet food. However, the field still lacks sufficient research to pinpoint the effects, potential, and direct efficacy of minor cannabinoids. Sanobiotec plans to help with that by implementing the pre-clinical study. Possibly, even with new partners found in this trade mission in Switzerland.